KEGG   NETWORK: N00259Help
Entry
N00259                      Network                                

Name
Amplified MET to RAS-ERK signaling pathway
Definition
MET* -> GRB2 -> SOS -> RAS -> RAF -> MEK -> ERK
  Expanded
4233v3 -> 2885 -> (6654,6655) -> (3265,3845,4893) -> (369,673,5894) -> (5604,5605) -> (5594,5595)
Class
nt06210 ERK signaling
nt06261 Gastric cancer
Type
Variant
Pathway
hsa05226  Gastric cancer
Disease
H00018  Gastric cancer
Gene
4233  MET; MET proto-oncogene, receptor tyrosine kinase
2885  GRB2; growth factor receptor bound protein 2
6654  SOS1; SOS Ras/Rac guanine nucleotide exchange factor 1
6655  SOS2; SOS Ras/Rho guanine nucleotide exchange factor 2
3265  HRAS; HRas proto-oncogene, GTPase
3845  KRAS; KRAS proto-oncogene, GTPase
4893  NRAS; NRAS proto-oncogene, GTPase
369  ARAF; A-Raf proto-oncogene, serine/threonine kinase
673  BRAF; B-Raf proto-oncogene, serine/threonine kinase
5894  RAF1; Raf-1 proto-oncogene, serine/threonine kinase
5604  MAP2K1; mitogen-activated protein kinase kinase 1
5605  MAP2K2; mitogen-activated protein kinase kinase 2
5594  MAPK1; mitogen-activated protein kinase 1
5595  MAPK3; mitogen-activated protein kinase 3
Variant
4233v3  MET amplification
Reference
  Authors
Appleman LJ
  Title
MET signaling pathway: a rational target for cancer therapy.
  Journal
J Clin Oncol 29:4837-8 (2011)
DOI:10.1200/JCO.2011.37.7929
Reference
  Authors
Feng Y, Ma PC
  Title
Anti-MET targeted therapy has come of age: the first durable complete response with MetMAb in metastatic gastric cancer.
  Journal
Cancer Discov 1:550-4 (2011)
DOI:10.1158/2159-8290.CD-11-0289
Reference
  Authors
Kawakami H, Okamoto I
  Title
MET-targeted therapy for gastric cancer: the importance of a biomarker-based strategy.
  Journal
Gastric Cancer 19:687-95 (2016)
DOI:10.1007/s10120-015-0585-x

DBGET integrated database retrieval system